Technical Analysis for MPSYF - Morphosys Ag

Grade Last Price % Change Price Change
grade A 109.7 -0.54% -0.6000
MPSYF closed down 0.54 percent on Tuesday, October 15, 2019, on 10.16 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical MPSYF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -0.54%
20 DMA Support Bullish -0.54%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.54%

Older signals for MPSYF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer�s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.Over 70 therapeutic antibody programs based on the company�s technologies are currently in development, of which 20 are in clinical trials. The company�s most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR208 and MOR202, both for the treatment of cancer.MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Medicine Healthcare Medical Specialties Cancer Pharmaceutical Industry Treatment Of Cancer Healthcare Products Immunology Antibodies Drug Development Monoclonal Antibodies Multiple Sclerosis Rheumatoid Arthritis Antibody Monoclonal Antibody Therapy Antibody Technology Cambridge Antibody Technology
Is MPSYF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 142.85
52 Week Low 36.63
Average Volume 3,740
200-Day Moving Average 84.8073
50-Day Moving Average 107.6886
20-Day Moving Average 110.3474
10-Day Moving Average 116.71
Average True Range 3.5452
ADX 11.32
+DI 44.6928
-DI 49.1941
Chandelier Exit (Long, 3 ATRs ) 112.8644
Chandelier Exit (Short, 3 ATRs ) 101.3856
Upper Bollinger Band 127.8668
Lower Bollinger Band 92.828
Percent B (%b) 0.48
BandWidth 31.753172
MACD Line 1.6588
MACD Signal Line 2.1045
MACD Histogram -0.4457
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 109.8500
Resistance 3 (R3) 109.8333 109.7667 109.8250
Resistance 2 (R2) 109.7667 109.7285 109.7750 109.8167
Resistance 1 (R1) 109.7333 109.7049 109.7500 109.7500 109.8083
Pivot Point 109.6667 109.6667 109.6750 109.6750 109.6667
Support 1 (S1) 109.6333 109.6285 109.6500 109.6500 109.5917
Support 2 (S2) 109.5667 109.6049 109.5750 109.5833
Support 3 (S3) 109.5333 109.5667 109.5750
Support 4 (S4) 109.5500